Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2876-2881

  Moore, Malcolm J ^a   Winquist, Eric W ^a   Murray, Nevin ^a   Tannock, Ian F ^a   Huan, Susan ^a   Bennett, Katherine ^a   Walsh, Wendy ^a   Seymour, Lesley ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PELVIS CARCINOMA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URETER CARCINOMA; UROGENITAL TRACT CANCER;

EID: 0032858246     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2876     Document Type: Article

References (17)

1. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
2. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma. J Clin Oncol 10:1066-1073, 1992
3. Saxman SB, Loehrer PJ, Propert K, et al: Long term follow up of phase III intergroup study of M-VAC vs. cisplatin in metastatic urothelial carcinoma. J Clin Oncol 15:2564-2569, 1997
4. Fossa SD, Scher HI, Sternberg C, et al: Survival of patients with advanced urothelial cancer treated with cisplatin based therapy. Br J Urol, 1996
5. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine. Cancer Res 50:4417-4422, 1990
6. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer. Ann Oncol 5:182-185, 1994
7. DeLena M, Gridelli C, Lorusso V, et al: Gemcitabine activity in resistant stage IV bladder cancer. Proc Am Soc Clin Oncol 15:246, 1996 (abstr)
8. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445, 1997
9. Stadler WM, Kuzel T, Roth B, et al: Phase II trial of gemcitabine in previously untreated patients with urothelial cancer. J Clin Oncol 14:3394-3398, 1997
10. Crino L, Scaglotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in non-small cell lung cancer: A phase II study. Proc Am Soc Clin Oncol 14:1066, 1995
11. von der Masse H, Andersen L, Crino L, et al: A phase II study of gemcitabine plus cisplatin in patients with transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 16:324a, 1997 (abstr 1155)
12. Kaufman D, Stadler WM, Carducci, et al: Gemcitabine plus cisplatin in metastatic urothelial cancer: Final results of a phase II study. Proc Am Soc Clin Oncol 17:320a, 1998 (abstr 1235)
13. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994
14. Einhorn LH, Roth BJ, Ansari R, et al: Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12:2271-2276, 1994
15. Redman BG, Smith DC, Flaherty L, et al: Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844-1848, 1998
16. Bajorin DR, McCaffrey JA, Hilton S, et al: Treatment of patients with transitional cell carcinoma of the urothelial tract with ifosfamide, paclitaxel and cisplatin: A phase II trial. J Clin Oncol 16:2722-2727, 1998
17. Bellmunt J, Carles J, Climent MA, et al: Phase I trial of paclitaxel, cisplatin and gemcitabine in advanced transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 17:321a, 1998 (abstr 1236)